The Value of a Trusted Wholesaler & Cole’s Act Update | TWIRx

Independent pharmacies need partners they can trust—and patients need a prescription-drug system that puts access ahead of profits. In this episode of This Week in Pharmacy, Todd Eury welcomes Rick Seipp, PharmD, President of Value Drug Company, to discuss the importance of choosing a dependable wholesale distribution partner. Following Smith Drug Company’s announced operational transition, Value Drug Company is prepared to help affected independent pharmacy owners evaluate their purchasing, distribution and operational needs while developing an orderly transition that protects continuity of service. For more than 90 years, pharmacist-led Value Drug Company has supported community pharmacies through transparent pricing, dependable distribution, collective purchasing power and programs designed to improve efficiency, growth and profitability. Rick explains how the company will provide transition assistance and regional gatherings where pharmacy owners can speak directly with Value Drug Company leadership. The episode also features a follow-up conversation with patient advocate Bil Schmidtknecht about the continuing fight for Cole’s Act. Named in memory of Bil’s son, Cole, the proposed reforms seek to protect patients from unexpected formulary and coverage changes that can suddenly make essential medications unaffordable. “Patients can’t afford more delays, and lives should never be collateral damage in a profit-driven system,” Bil says. The discussion examines PBM accountability, medication affordability and why families must receive meaningful notice before coverage changes place lifesaving treatments beyond their reach. TWIRx News: Week Ending August 14, 2026 Employers Are Moving Away from the “Big Three” PBMs A new employer survey points to growing disruption in the PBM marketplace. Forty-six percent of surveyed employers reported using a PBM outside CVS Caremark, Express Scripts and Optum Rx—up from 37% the previous year. Employers are increasingly seeking transparent pricing, access to claims data and greater control over prescription-drug spending. Read the Axios report FDA Delays Major iPLEDGE Changes Until November The FDA has postponed implementation of updated iPLEDGE REMS requirements from August 8 to November 15, 2026, to allow additional system testing. The forthcoming changes are intended to reduce burdens on patients, pharmacists and prescribers while maintaining safeguards surrounding isotretinoin. Read the FDA iPLEDGE update Episode Resources Value Drug Company transition-support announcement Value Drug Company transition assistance: 1-866-226-1772 Patient Protector Modern Medical Mafia: PBM Reform Pharmacy Podcast Network About the Guests Rick Seipp, PharmD President, Value Drug Company Bil Schmidtknecht Patient advocate and father of Cole Schmidtknecht